AstraZeneca PLC Q4 2024 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: James Gordon - JPMorgan - Analyst : Thanks for taking the question. James Gordon from JP Morgan. I'll stick to one theme, which will be China. So a couple of questions on China. So one would be, some revenues down 3% in Q4. But how did it evolve during the quarter? So what did it look like before there was the investigation on November 5 versus afterwards? And more recently, like the start of this year, are things getting better or worse in China? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. FEBRUARY 06, 2025 / 11:00AM, AZN.L - Q4 2024 AstraZeneca PLC Earnings Call Also in China, so for 2025, so you've given us a group guide, but what does that seem for China? And I can see we've got Lynparza and probably Farxiga VBP. So should we assume that China is going to decline overall, not just because of the investigation but also VBP, but EM overall still grows, how to think about that? And then just finally, on China. So I think there've been investigations going for some time, but I've not seen any provision for a fine or other penalty in your disclosures. So how should we read that? Does that mean you don't think there is likelihood that you're going to have to pay something material? Or is it just you wouldn't provision for it at this time? When would you have to have a provision for something?